High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules
暂无分享,去创建一个
Jingyun Shi | S. Ren | Caicun Zhou | G. Gao | G. Schmid‐Bindert | L. Hou | Xue-Fei Li | Chao Zhao | Yayi He | Haiqing Chu | Yang Yang | Chunyan Wu | Jun Zhang
[1] Travis M. Drucker,et al. Identification of independent primary tumors and intrapulmonary metastases using DNA rearrangements in non-small-cell lung cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Guotong Xu,et al. Epithelial phenotype as a predictive marker for response to EGFR‐TKIs in non‐small cell lung cancer patients with wild‐type EGFR , 2014, International journal of cancer.
[3] E. Chae,et al. Surgical management of pulmonary adenocarcinoma presenting as a pure ground-glass nodule. , 2014, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[4] Yang Zhang,et al. Synchronous Non-small Cell Lung Cancers: Diagnostic Yield can be Improved by Histologic and Genetic Methods , 2014, Annals of Surgical Oncology.
[5] Jingyun Shi,et al. T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients. , 2014, Lung cancer.
[6] F. Hirsch,et al. Atypical negative ALK break-apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer. , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[7] G. Jiang,et al. Surgical algorithm for heterogeneous bilateral quadruple pulmonary nodules. , 2013, Interactive cardiovascular and thoracic surgery.
[8] Mark J. Ratain,et al. Tumour heterogeneity in the clinic , 2013, Nature.
[9] C. Zhou,et al. ROS1 fusions in Chinese patients with non-small-cell lung cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] F. Detterbeck,et al. Special treatment issues in non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. , 2013, Chest.
[11] A. Chang,et al. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. , 2013, Chest.
[12] Caicun Zhou,et al. KIF5B‐RET fusions in Chinese patients with non–small cell lung cancer , 2013, Cancer.
[13] 荒井 淳一. Clinical and molecular analysis of synchronous double lung cancers , 2013 .
[14] Qinghua Zhou,et al. Detection and Clinical Significance of Intratumoral EGFR Mutational Heterogeneity in Chinese Patients with Advanced Non-Small Cell Lung Cancer , 2013, PloS one.
[15] T. Mok,et al. EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas. , 2012, The oncologist.
[16] S. Ren,et al. Analysis of Driver Mutations in Female Non-Smoker Asian Patients with Pulmonary Adenocarcinoma , 2012, Cell Biochemistry and Biophysics.
[17] S. Ren,et al. Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never‐smoker women with pulmonary adenocarcinoma , 2012, Cancer.
[18] Charles Swanton,et al. Intratumor Heterogeneity: Seeing the Wood for the Trees , 2012, Science Translational Medicine.
[19] P. A. Futreal,et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.
[20] F. Detterbeck,et al. Approach to the ground-glass nodule. , 2011, Clinics in chest medicine.
[21] D. Clark,et al. EGFR and KRAS mutations in metastatic lung adenocarcinomas. , 2011, Human pathology.
[22] Masahiro Tsuboi,et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[23] C. Lee,et al. Epidermal Growth Factor Receptor Mutation and p53 Overexpression during the Multistage Progression of Small Adenocarcinoma of the Lung , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[24] Yong Soo Choi,et al. Management of Multiple Pure Ground-Glass Opacity Lesions in Patients with Bronchioloalveolar Carcinoma , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[25] Jae Ho Lee,et al. Epidermal Growth Factor Receptor Mutation and Pathologic-Radiologic Correlation Between Multiple Lung Nodules with Ground-Glass Opacity Differentiates Multicentric Origin from Intrapulmonary Spread , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[26] Myrna C B Godoy,et al. Subsolid pulmonary nodules and the spectrum of peripheral adenocarcinomas of the lung: recommended interim guidelines for assessment and management. , 2009, Radiology.
[27] C. Pirker,et al. EGFR/KRAS/BRAF Mutations in Primary Lung Adenocarcinomas and Corresponding Locoregional Lymph Node Metastases , 2009, Clinical Cancer Research.
[28] P. Jänne,et al. Discordance of Molecular Biomarkers Associated with Epidermal Growth Factor Receptor Pathway between Primary Tumors and Lymph Node Metastasis in Non-small Cell Lung Cancer , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[29] Tae Jung Kim,et al. Clinical, pathological and thin-section CT features of persistent multiple ground-glass opacity nodules: comparison with solitary ground-glass opacity nodule. , 2009, Lung cancer.
[30] K. Iyama,et al. Epidermal Growth Factor Receptor Mutations in Multicentric Lung Adenocarcinomas and Atypical Adenomatous Hyperplasias , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[31] G. Rossi,et al. A subset of lung adenocarcinomas and atypical adenomatous hyperplasia-associated foci are genotypically related: an EGFR, HER2, and K-ras mutational analysis. , 2008, American journal of clinical pathology.
[32] H. Aburatani,et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.
[33] J. Yokota,et al. Frequent EGFR mutations in brain metastases of lung adenocarcinoma , 2006, International journal of cancer.
[34] Kenji Suzuki,et al. A clinicopathological study of resected subcentimeter lung cancers: a favorable prognosis for ground glass opacity lesions. , 2003, The Annals of thoracic surgery.
[35] D. Shibata,et al. c-k-ras and p53 mutations occur very early in adenocarcinoma of the lung. , 1994, The American journal of pathology.
[36] Yoshiro,et al. Genesis of squamous cell lung carcinoma. Sequential changes of proliferation, DNA ploidy, and p53 expression. , 1994, The American journal of pathology.
[37] M. Ferguson,et al. Synchronous primary lung cancers. , 1993, Chest.
[38] Kyung Soo Lee,et al. Natural history of pure ground-glass opacity lung nodules detected by low-dose CT scan. , 2013, Chest.
[39] N. Girard,et al. Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines. , 2010, Chest.
[40] F. Detterbeck,et al. Lung cancer. Special treatment issues. , 2003, Chest.